We use cookies to provide some features and experiences in QOSHE

More information  .  Close
Aa Aa Aa
- A +

Here's Why You Should Add Omnicell (OMCL) to Your Portfolio

4 12 1

Omnicell, Inc. OMCL is well poised for growth backed by its strategic acquisitions and partnerships. The raised guidance for 2021 buoys optimism as well. The 2025 roadmap looks encouraging along with the good solvency position.

Over the past year, the Zacks Rank #1 (Strong Buy) stock has gained 119.1% against the 17.9% fall of the industry and 35.1% rise of the S&P 500.

The renowned medical device solutions provider has a market capitalization of $6.79 billion. Its second-quarter 2021 earnings beat the Zacks Consensus Estimate by 21.3%. The company projects 16% growth for the next five years. Further, the company surpassed estimates in the trailing four quarters, the average surprise being 17.74%.

Let’s delve deeper.

Strategic Imperatives to Drive Growth: Omnicell is progressing well with its three-legged strategy that covers market expansion through the delivery of differentiated, innovative solutions; expansion into new markets, primarily outside the United States; and expansion through strategic tie-ups and acquisition of new technologies.

In line with this, the company has accelerated a shift to cloud-based solutions and tech-enabled services through the launches of Omnicell One and Central Pharmacy Dispensing Services. In 2021, the company has seen rapid........

© Entrepreneur

Get it on Google Play